Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing

Overview

cited authors

Benoit, Stefanie W.; Fukuda, Tsuyoshi; Vanden Heuvel, Katherine; Witte, David; Fuller, Christine; Willis, Jennifer; Dixon, Bradley P.; Drake, Keri A.

Publication Date

February 23, 2022

webpage

Web of Science

published in

FRONTIERS IN PEDIATRICS Journal

Research

keywords

Bayesian modeling
atypical HUS
eculizumab
rhabdomyolysis
therapeutic drug monitoring

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.